{"id":"placebo-semaglutide","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo semaglutide is used as a control comparator in clinical trials. It contains no semaglutide or other active agent and serves to establish the baseline effect of treatment expectation and study procedures, allowing researchers to isolate the true pharmacological effects of active semaglutide through comparison.","oneSentence":"Placebo semaglutide is an inactive formulation containing no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:25.855Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT04777409","phase":"PHASE3","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-18","conditions":"Early Alzheimer´s Disease","enrollment":1840},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT07227948","phase":"PHASE2","title":"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-15","conditions":"Cocaine Use Disorder","enrollment":75},{"nctId":"NCT06989177","phase":"NA","title":"Probiotic Intervention on Body Weight","status":"RECRUITING","sponsor":"Chinese Academy of Sciences","startDate":"2025-06-10","conditions":"Obesity, Homeostasis, Weight Loss","enrollment":140},{"nctId":"NCT06989203","phase":"NA","title":"Protein Supplementation Intervention on Body Weight","status":"RECRUITING","sponsor":"Chinese Academy of Sciences","startDate":"2025-06-10","conditions":"Obesity, Weight Loss, Protein Supplementation","enrollment":140},{"nctId":"NCT07221214","phase":"PHASE2","title":"GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-03-31","conditions":"HIV, Alcohol, Smoking Cigarette","enrollment":200},{"nctId":"NCT07284979","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-30","conditions":"Obesity","enrollment":1200},{"nctId":"NCT06409130","phase":"PHASE2","title":"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-20","conditions":"Alcohol-related Liver Disease","enrollment":270},{"nctId":"NCT07400107","phase":"PHASE3","title":"AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-05-20","conditions":"Obesity, Overweight, Diabetes Mellitus, Type 2","enrollment":1000},{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT07112872","phase":"PHASE2","title":"A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-08-19","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT07465965","phase":"PHASE1","title":"A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults","status":"RECRUITING","sponsor":"Shanghai World Leader Pharmaceutical Co., Ltd.","startDate":"2026-03-02","conditions":"Overweight, Obesity","enrollment":60},{"nctId":"NCT05669755","phase":"PHASE3","title":"REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-03-01","conditions":"Cardiovascular Disease","enrollment":7101},{"nctId":"NCT05649137","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":512},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT03811561","phase":"PHASE3","title":"A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-05-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1500},{"nctId":"NCT07415954","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-04-17","conditions":"Diabetes Mellitus, Type 2","enrollment":270},{"nctId":"NCT07249554","phase":"PHASE2","title":"Combination Therapy for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT05371496","phase":"PHASE2","title":"Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2022-09-06","conditions":"Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity","enrollment":81},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT05819138","phase":"PHASE3","title":"Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-21","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT06982859","phase":"PHASE1","title":"A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-02","conditions":"Diabetes Mellitus, Insulin Sensitivity","enrollment":95},{"nctId":"NCT07446439","phase":"PHASE3","title":"A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","status":"NOT_YET_RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2026-02-25","conditions":"Nausea and Vomiting, Obesity","enrollment":280},{"nctId":"NCT06897475","phase":"PHASE2","title":"A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-28","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06814938","phase":"PHASE4","title":"A Study of a Novel Precision Medicine Approach For Obesity","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-21","conditions":"Obesity","enrollment":135},{"nctId":"NCT04019197","phase":"PHASE2","title":"Effects of Semaglutide in HIV-Associated Lipohypertrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Western Reserve University","startDate":"2019-05-16","conditions":"HIV/AIDS, Lipohypertrophy, Obesity","enrollment":108},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT05564117","phase":"PHASE3","title":"Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-10-11","conditions":"Overweight, Obesity","enrollment":307},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT07172867","phase":"PHASE2","title":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","status":"WITHDRAWN","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":""},{"nctId":"NCT05891496","phase":"PHASE3","title":"A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-20","conditions":"Alzheimers Disease","enrollment":23},{"nctId":"NCT07430332","phase":"PHASE2","title":"GLP-1 RA for Stage 1 Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2027-09-01","conditions":"Stage 1 Diabetes Mellitus, Type 1","enrollment":15},{"nctId":"NCT06015893","phase":"PHASE2","title":"Semaglutide Therapy for Alcohol Reduction (STAR)","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-10-17","conditions":"Addiction, Alcohol Use Disorder","enrollment":52},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":"Obesity, Muscle Loss","enrollment":120},{"nctId":"NCT04822181","phase":"PHASE3","title":"Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-04-01","conditions":"Non-alcoholic Steatohepatitis","enrollment":1205},{"nctId":"NCT07411378","phase":"PHASE2","title":"Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","status":"NOT_YET_RECRUITING","sponsor":"Biophytis","startDate":"2026-07","conditions":"Muscle Wasting, Obesity & Overweight, Obesity","enrollment":164},{"nctId":"NCT07401992","phase":"PHASE4","title":"Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-01-15","conditions":"Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2","enrollment":62},{"nctId":"NCT06173778","phase":"PHASE2","title":"Semaglutide for Post-Smoking Cessation Weight Management","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-04-23","conditions":"Obesity, Overweight, Cigarette Smoking","enrollment":197},{"nctId":"NCT06608433","phase":"NA","title":"Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-16","conditions":"Healthy Volunteer Study, HPA, Cortisol Deficiency","enrollment":22},{"nctId":"NCT04865770","phase":"PHASE3","title":"A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-28","conditions":"Diabetes Mellitus, Type 2, Chronic Kidney Disease","enrollment":106},{"nctId":"NCT04779697","phase":"PHASE1","title":"GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-01","conditions":"Obesity","enrollment":96},{"nctId":"NCT06050577","phase":"PHASE2","title":"The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-06-07","conditions":"Type 2 Diabetes, Osteopenia","enrollment":64},{"nctId":"NCT06388187","phase":"PHASE3","title":"A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-06-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT07282613","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-04","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":"Major Depressive Disorder","enrollment":116},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT06914102","phase":"","title":"Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-01-14","conditions":"Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":58387},{"nctId":"NCT04777396","phase":"PHASE3","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-05-18","conditions":"Early Alzheimer's Disease","enrollment":1840},{"nctId":"NCT05040971","phase":"PHASE3","title":"Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-09-06","conditions":"Obesity","enrollment":207},{"nctId":"NCT04251156","phase":"PHASE3","title":"Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-12-08","conditions":"Overweight, Obesity, Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT05394519","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-01","conditions":"Overweight, Obesity, Type 2 Diabetes Mellitus","enrollment":1200},{"nctId":"NCT07253285","phase":"PHASE3","title":"A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-01-08","conditions":"Overweight, Obesity","enrollment":460},{"nctId":"NCT06390501","phase":"NA","title":"The Effect of Weekly Semaglutide Treatment on Energy Expenditure","status":"COMPLETED","sponsor":"Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences","startDate":"2024-04-01","conditions":"Obesity; Drug","enrollment":60},{"nctId":"NCT05890976","phase":"PHASE3","title":"Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-05-30","conditions":"Overweight, Obesity","enrollment":200},{"nctId":"NCT05813925","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-04-03","conditions":"Obesity or Overweight","enrollment":331},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT06780449","phase":"PHASE3","title":"A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-02-10","conditions":"Obesity","enrollment":400},{"nctId":"NCT06577090","phase":"PHASE2","title":"Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Skye Bioscience, Inc.","startDate":"2024-08-22","conditions":"Obesity","enrollment":136},{"nctId":"NCT06323174","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-19","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT06579105","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-08","conditions":"Diabetes Mellitus, Type 2","enrollment":406},{"nctId":"NCT06042153","phase":"PHASE4","title":"DIALYSIS-TIR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-12-05","conditions":"Type 2 Diabetes, End Stage Renal Disease on Dialysis","enrollment":43},{"nctId":"NCT06041217","phase":"PHASE3","title":"A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-15","conditions":"Overweight, Obesity","enrollment":242},{"nctId":"NCT05877547","phase":"PHASE2","title":"A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-23","conditions":"Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD","enrollment":381},{"nctId":"NCT05829460","phase":"PHASE2","title":"Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2025-03-12","conditions":"Endometrial Hyperplasia","enrollment":""},{"nctId":"NCT05996848","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-08-15","conditions":"Obesity or Overweight","enrollment":300},{"nctId":"NCT06207877","phase":"PHASE1","title":"A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-23","conditions":"Obesity","enrollment":62},{"nctId":"NCT04969939","phase":"PHASE2","title":"A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-07-15","conditions":"Obesity","enrollment":120},{"nctId":"NCT06267092","phase":"PHASE1","title":"A Study of How CagriSema Works on Appetite in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Overweight, Obesity","enrollment":164},{"nctId":"NCT07218354","phase":"PHASE3","title":"Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":438},{"nctId":"NCT04998136","phase":"PHASE3","title":"Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-15","conditions":"Obesity","enrollment":150},{"nctId":"NCT05702931","phase":"PHASE4","title":"Semaglutide Treatment for Hyperglycaemia After Renal Transplantation","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-09-19","conditions":"Hyperglycemia, Renal Transplant Complication Primary Non-Function, Diabetes","enrollment":104},{"nctId":"NCT06801015","phase":"PHASE4","title":"Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT05892432","phase":"PHASE2","title":"Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2024-01-11","conditions":"Alcohol Use Disorder","enrollment":50},{"nctId":"NCT07220629","phase":"PHASE2","title":"Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NodThera Limited","startDate":"2025-10-02","conditions":"Obesity","enrollment":80},{"nctId":"NCT06640972","phase":"PHASE2","title":"Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2024-09-27","conditions":"Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated","enrollment":68},{"nctId":"NCT04982575","phase":"PHASE2","title":"Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT07297238","phase":"NA","title":"Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.","status":"NOT_YET_RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2026-01-01","conditions":"Short Bowel Syndrome (SBS), Intestinal Failure","enrollment":20},{"nctId":"NCT05574439","phase":"PHASE4","title":"Young Adults With Early-onset Obesity Treated With Semaglutide","status":"RECRUITING","sponsor":"Signe Torekov","startDate":"2022-06-01","conditions":"Obesity, Adolescent","enrollment":180},{"nctId":"NCT06338553","phase":"EARLY_PHASE1","title":"GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-12","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT06972992","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide","status":"COMPLETED","sponsor":"Ascletis Pharma (China) Co., Limited","startDate":"2025-04-18","conditions":"Chronic Weight Management","enrollment":28},{"nctId":"NCT05891587","phase":"PHASE2","title":"Semaglutide Therapy for Alcohol Reduction - Tulsa","status":"COMPLETED","sponsor":"Oklahoma State University Center for Health Sciences","startDate":"2023-07-07","conditions":"Alcohol Use Disorder","enrollment":80},{"nctId":"NCT06299098","phase":"PHASE2","title":"A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-03-13","conditions":"Obesity","enrollment":1005},{"nctId":"NCT04560998","phase":"PHASE3","title":"A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-01","conditions":"Diabetes Mellitus, Type 2, Peripheral Arterial Disease","enrollment":792},{"nctId":"NCT05486065","phase":"PHASE2","title":"A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-08","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT07011667","phase":"PHASE3","title":"A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-03","conditions":"Obesity","enrollment":609},{"nctId":"NCT04102189","phase":"PHASE3","title":"A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-10-07","conditions":"Overweight, Obesity","enrollment":201},{"nctId":"NCT03914326","phase":"PHASE3","title":"A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-06-17","conditions":"Diabetes Mellitus, Type 2","enrollment":9651},{"nctId":"NCT05646706","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity","enrollment":1407},{"nctId":"NCT05567796","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2022-11-01","conditions":"Obesity","enrollment":3400},{"nctId":"NCT04788511","phase":"PHASE3","title":"Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-16","conditions":"Obesity","enrollment":529},{"nctId":"NCT06797869","phase":"PHASE2","title":"A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-29","conditions":"Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","enrollment":142},{"nctId":"NCT05035095","phase":"PHASE3","title":"Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-09-13","conditions":"Obesity, Overweight","enrollment":667},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT06131372","phase":"PHASE2","title":"A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes, Obesity","enrollment":626},{"nctId":"NCT07254715","phase":"PHASE4","title":"Effect of Itopride on Semaglutide Gastroparesis","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-12","conditions":"Semaglutide-Induced Gastric Motility, Anesthesia","enrollment":60},{"nctId":"NCT04916470","phase":"PHASE3","title":"Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-15","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2","enrollment":617},{"nctId":"NCT04971785","phase":"PHASE2","title":"Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-08-09","conditions":"Nonalcoholic Steatohepatitis","enrollment":457},{"nctId":"NCT05144984","phase":"PHASE2","title":"A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rybelsus","Placebo semaglutide","Rybelsus tablet"],"phase":"marketed","status":"active","brandName":"Placebo semaglutide","genericName":"Placebo semaglutide","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo semaglutide is an inactive formulation containing no active pharmaceutical ingredient and produces no pharmacological effect. Used for Clinical trial control comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}